CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions [2] - The company is commercializing its lead product DefenCath® (taurolidine and heparin), which received FDA approval on November 15, 2023 [2] - DefenCath was launched in inpatient settings in April 2024 and in outpatient settings in July 2024 [2] Upcoming Events - Management will participate in the 24th Annual Needham Virtual Healthcare Conference from April 7-10, 2025 [1] - A fireside chat is scheduled for April 8, 2025, at 2:15 p.m. EDT [2] Clinical Development - CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 [2] - The company intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas [2]